Charles River Laboratories (CRL) Tops Q2 EPS by 5c, beats revenue, offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $345.37 +1.68%
Revenue Growth %: -4.0%
Financial Fact:
Operating income: 58.8M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: -4.0%
Financial Fact:
Operating income: 58.8M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $2.69, $0.05 better than the analyst estimate of $2.64. Revenue for the quarter came in at $1.06 billion versus the consensus estimate of $1.05 billion.
GUIDANCE:
Charles River Laboratories sees FY2023 EPS of $10.30-$10.90.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Top restaurant stocks to watch, according to Raymond James
- AMTD Digital reports $1.2B in total assets, $42.4M profit
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
